Overview

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Status:
Completed
Trial end date:
2019-03-23
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
Phase:
Phase 3
Details
Lead Sponsor:
Radiomedix, Inc.
Treatments:
Somatostatin